No Cover Image

Journal article 235 views 35 downloads

Exploratory outcomes of the use of insulin degludec in the real world: data from the Association of British Clinical Diabetologists nationwide degludec audit

Santo Colosimo, Yue Ruan, Alistair Lumb, Rustam Rea, Paula McDonald, Steve Bain Orcid Logo, Ralph Abraham, Ian Gallen, Robert Ryder

British Journal of Diabetes, Volume: 24, Issue: 1, Pages: 45 - 50

Swansea University Author: Steve Bain Orcid Logo

  • 66210.VoR.pdf

    PDF | Version of Record

    © The authors 2024. This work is openly licensed via CC BY 4.0.

    Download (490.34KB)

Check full text

DOI (Published version): 10.15277/bjd.2024.448

Abstract

Insulin degludec is a long-acting basal insulin analog that is used as a single daily injection in people living with type 2 diabetes (T2DM) or in combination with rapid-acting analogs in basal-bolus regimens in people living with T2DM or type 1 diabetes (T1DM). Registration studies showed benefits...

Full description

Published in: British Journal of Diabetes
ISSN: 2397-6233 2397-6241
Published: ABCD Diabetes Care, Ltd. 2024
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa66210
first_indexed 2024-04-29T11:29:39Z
last_indexed 2024-11-25T14:17:41Z
id cronfa66210
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2024-07-25T13:42:35.3566668</datestamp><bib-version>v2</bib-version><id>66210</id><entry>2024-04-29</entry><title>Exploratory outcomes of the use of insulin degludec in the real world: data from the Association of British Clinical Diabetologists nationwide degludec audit</title><swanseaauthors><author><sid>5399f4c6e6a70f3608a084ddb938511a</sid><ORCID>0000-0001-8519-4964</ORCID><firstname>Steve</firstname><surname>Bain</surname><name>Steve Bain</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2024-04-29</date><deptcode>MEDS</deptcode><abstract>Insulin degludec is a long-acting basal insulin analog that is used as a single daily injection in people living with type 2 diabetes (T2DM) or in combination with rapid-acting analogs in basal-bolus regimens in people living with T2DM or type 1 diabetes (T1DM). Registration studies showed benefits of reduction of hypoglycaemia rate and severity compared to previously available long-acting insulins.The Association of British Clinical Diabetologists nationwide clinical audit of insulin degludec is a real-world data program which includes a secondary care prospective data collection and a primary care retrospective data collection. Data were used to investigate the effects of degludec initiation in people living with T1DM or T2DM on hypoglycaemia rate and severity, change in haemoglobin A1c (HbA1c) and weight change.From the secondary care prospective and the primary care retrospective data 432 (of whom T1DM=273) and 3,513 (of whom T1DM=2,040) patients, respectively, were included in the analysis. HbA1c change was non-significant in people with T1DM and T2DM who were switched to insulin degludec due to hypoglycaemia in the secondary care cohort. A significant reduction of 3 and 10 mmol/mol was observed in people with T1DM and T2DM, respectively, when the switch to degludec was prompted by reasons other than hypoglycaemia, and in people with T1DM this was also associated with a 2.5 kg weight gain. There was a clinically significant reduction in minor, severe and nocturnal hypoglycaemia in 62%, 45% and 54% of T1DM and in minor hypoglycaemia in 44% of T2DM in the prospective cohort.Insulin degludec reduced HbA1c in people with diabetes who were started for non-hypoglycaemia reasons and in people in the retrospective cohort. The extent of reduction in HbA1c was similar in both cohorts, even after stratification for T1DM and T2DM. Overall, insulin degludec resulted in lower HbA1c and modest weight gain in people starting for non- hypoglycaemia reasons and lower hypoglycaemia without any change in HbA1c or weight in people switching due to hypoglycaemia.</abstract><type>Journal Article</type><journal>British Journal of Diabetes</journal><volume>24</volume><journalNumber>1</journalNumber><paginationStart>45</paginationStart><paginationEnd>50</paginationEnd><publisher>ABCD Diabetes Care, Ltd.</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint>2397-6233</issnPrint><issnElectronic>2397-6241</issnElectronic><keywords>basal insulin, insulin degludec, glucose control, real world data, hypoglycaemia</keywords><publishedDay>29</publishedDay><publishedMonth>6</publishedMonth><publishedYear>2024</publishedYear><publishedDate>2024-06-29</publishedDate><doi>10.15277/bjd.2024.448</doi><url/><notes/><college>COLLEGE NANME</college><department>Medical School</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>MEDS</DepartmentCode><institution>Swansea University</institution><apcterm>Another institution paid the OA fee</apcterm><funders/><projectreference/><lastEdited>2024-07-25T13:42:35.3566668</lastEdited><Created>2024-04-29T12:25:51.9288088</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Biomedical Science</level></path><authors><author><firstname>Santo</firstname><surname>Colosimo</surname><order>1</order></author><author><firstname>Yue</firstname><surname>Ruan</surname><order>2</order></author><author><firstname>Alistair</firstname><surname>Lumb</surname><order>3</order></author><author><firstname>Rustam</firstname><surname>Rea</surname><order>4</order></author><author><firstname>Paula</firstname><surname>McDonald</surname><order>5</order></author><author><firstname>Steve</firstname><surname>Bain</surname><orcid>0000-0001-8519-4964</orcid><order>6</order></author><author><firstname>Ralph</firstname><surname>Abraham</surname><order>7</order></author><author><firstname>Ian</firstname><surname>Gallen</surname><order>8</order></author><author><firstname>Robert</firstname><surname>Ryder</surname><order>9</order></author></authors><documents><document><filename>66210__30983__d4d2183001ae4703b8ee50cd2f2e8dc4.pdf</filename><originalFilename>66210.VoR.pdf</originalFilename><uploaded>2024-07-25T13:40:45.1360537</uploaded><type>Output</type><contentLength>502104</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>&#xA9; The authors 2024. This work is openly licensed via CC BY 4.0.</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>https://creativecommons.org/licenses/by/4.0/</licence></document></documents><OutputDurs/></rfc1807>
spelling 2024-07-25T13:42:35.3566668 v2 66210 2024-04-29 Exploratory outcomes of the use of insulin degludec in the real world: data from the Association of British Clinical Diabetologists nationwide degludec audit 5399f4c6e6a70f3608a084ddb938511a 0000-0001-8519-4964 Steve Bain Steve Bain true false 2024-04-29 MEDS Insulin degludec is a long-acting basal insulin analog that is used as a single daily injection in people living with type 2 diabetes (T2DM) or in combination with rapid-acting analogs in basal-bolus regimens in people living with T2DM or type 1 diabetes (T1DM). Registration studies showed benefits of reduction of hypoglycaemia rate and severity compared to previously available long-acting insulins.The Association of British Clinical Diabetologists nationwide clinical audit of insulin degludec is a real-world data program which includes a secondary care prospective data collection and a primary care retrospective data collection. Data were used to investigate the effects of degludec initiation in people living with T1DM or T2DM on hypoglycaemia rate and severity, change in haemoglobin A1c (HbA1c) and weight change.From the secondary care prospective and the primary care retrospective data 432 (of whom T1DM=273) and 3,513 (of whom T1DM=2,040) patients, respectively, were included in the analysis. HbA1c change was non-significant in people with T1DM and T2DM who were switched to insulin degludec due to hypoglycaemia in the secondary care cohort. A significant reduction of 3 and 10 mmol/mol was observed in people with T1DM and T2DM, respectively, when the switch to degludec was prompted by reasons other than hypoglycaemia, and in people with T1DM this was also associated with a 2.5 kg weight gain. There was a clinically significant reduction in minor, severe and nocturnal hypoglycaemia in 62%, 45% and 54% of T1DM and in minor hypoglycaemia in 44% of T2DM in the prospective cohort.Insulin degludec reduced HbA1c in people with diabetes who were started for non-hypoglycaemia reasons and in people in the retrospective cohort. The extent of reduction in HbA1c was similar in both cohorts, even after stratification for T1DM and T2DM. Overall, insulin degludec resulted in lower HbA1c and modest weight gain in people starting for non- hypoglycaemia reasons and lower hypoglycaemia without any change in HbA1c or weight in people switching due to hypoglycaemia. Journal Article British Journal of Diabetes 24 1 45 50 ABCD Diabetes Care, Ltd. 2397-6233 2397-6241 basal insulin, insulin degludec, glucose control, real world data, hypoglycaemia 29 6 2024 2024-06-29 10.15277/bjd.2024.448 COLLEGE NANME Medical School COLLEGE CODE MEDS Swansea University Another institution paid the OA fee 2024-07-25T13:42:35.3566668 2024-04-29T12:25:51.9288088 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Biomedical Science Santo Colosimo 1 Yue Ruan 2 Alistair Lumb 3 Rustam Rea 4 Paula McDonald 5 Steve Bain 0000-0001-8519-4964 6 Ralph Abraham 7 Ian Gallen 8 Robert Ryder 9 66210__30983__d4d2183001ae4703b8ee50cd2f2e8dc4.pdf 66210.VoR.pdf 2024-07-25T13:40:45.1360537 Output 502104 application/pdf Version of Record true © The authors 2024. This work is openly licensed via CC BY 4.0. true eng https://creativecommons.org/licenses/by/4.0/
title Exploratory outcomes of the use of insulin degludec in the real world: data from the Association of British Clinical Diabetologists nationwide degludec audit
spellingShingle Exploratory outcomes of the use of insulin degludec in the real world: data from the Association of British Clinical Diabetologists nationwide degludec audit
Steve Bain
title_short Exploratory outcomes of the use of insulin degludec in the real world: data from the Association of British Clinical Diabetologists nationwide degludec audit
title_full Exploratory outcomes of the use of insulin degludec in the real world: data from the Association of British Clinical Diabetologists nationwide degludec audit
title_fullStr Exploratory outcomes of the use of insulin degludec in the real world: data from the Association of British Clinical Diabetologists nationwide degludec audit
title_full_unstemmed Exploratory outcomes of the use of insulin degludec in the real world: data from the Association of British Clinical Diabetologists nationwide degludec audit
title_sort Exploratory outcomes of the use of insulin degludec in the real world: data from the Association of British Clinical Diabetologists nationwide degludec audit
author_id_str_mv 5399f4c6e6a70f3608a084ddb938511a
author_id_fullname_str_mv 5399f4c6e6a70f3608a084ddb938511a_***_Steve Bain
author Steve Bain
author2 Santo Colosimo
Yue Ruan
Alistair Lumb
Rustam Rea
Paula McDonald
Steve Bain
Ralph Abraham
Ian Gallen
Robert Ryder
format Journal article
container_title British Journal of Diabetes
container_volume 24
container_issue 1
container_start_page 45
publishDate 2024
institution Swansea University
issn 2397-6233
2397-6241
doi_str_mv 10.15277/bjd.2024.448
publisher ABCD Diabetes Care, Ltd.
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Biomedical Science{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Biomedical Science
document_store_str 1
active_str 0
description Insulin degludec is a long-acting basal insulin analog that is used as a single daily injection in people living with type 2 diabetes (T2DM) or in combination with rapid-acting analogs in basal-bolus regimens in people living with T2DM or type 1 diabetes (T1DM). Registration studies showed benefits of reduction of hypoglycaemia rate and severity compared to previously available long-acting insulins.The Association of British Clinical Diabetologists nationwide clinical audit of insulin degludec is a real-world data program which includes a secondary care prospective data collection and a primary care retrospective data collection. Data were used to investigate the effects of degludec initiation in people living with T1DM or T2DM on hypoglycaemia rate and severity, change in haemoglobin A1c (HbA1c) and weight change.From the secondary care prospective and the primary care retrospective data 432 (of whom T1DM=273) and 3,513 (of whom T1DM=2,040) patients, respectively, were included in the analysis. HbA1c change was non-significant in people with T1DM and T2DM who were switched to insulin degludec due to hypoglycaemia in the secondary care cohort. A significant reduction of 3 and 10 mmol/mol was observed in people with T1DM and T2DM, respectively, when the switch to degludec was prompted by reasons other than hypoglycaemia, and in people with T1DM this was also associated with a 2.5 kg weight gain. There was a clinically significant reduction in minor, severe and nocturnal hypoglycaemia in 62%, 45% and 54% of T1DM and in minor hypoglycaemia in 44% of T2DM in the prospective cohort.Insulin degludec reduced HbA1c in people with diabetes who were started for non-hypoglycaemia reasons and in people in the retrospective cohort. The extent of reduction in HbA1c was similar in both cohorts, even after stratification for T1DM and T2DM. Overall, insulin degludec resulted in lower HbA1c and modest weight gain in people starting for non- hypoglycaemia reasons and lower hypoglycaemia without any change in HbA1c or weight in people switching due to hypoglycaemia.
published_date 2024-06-29T06:11:14Z
_version_ 1830350093791789056
score 11.317152

Similar Items